To Assess the Safety of Continuous IV Administration of the CXCR4 Antagonist, Plerixafor (Mozobil), and Assess Its Impact on the Immune Microenvironment in Patients With Advanced Pancreatic, High Grade Serous Ovarian and Colorectal Adenocarcinomas.
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Plerixafor (Primary)
- Indications Colorectal cancer; Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions
- Acronyms CAM-PLEX
- 12 Jan 2018 Last checked against ClinicalTrials.gov record
- 08 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 08 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.